Navtemadlin not checked

Kartos Therapeutics, Inc. · KRT-232

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
12 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth”In the company’s words, NCT05797831 on ClinicalTrials.gov
Tested for
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF, Endometrial Cancer, Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and 1 more
Main trialPhase 3
“This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a…”In the company’s words, NCT06479135 on ClinicalTrials.gov
Other names
KRT-232

Other drugs for Myelofibrosis

All 37 drugs for Myelofibrosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2026 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Phase 2/3Recruiting Aug 2025 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Phase 1/2Recruiting Oct 2022 Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Phase 2/3Unknown 31 Dec 2023 KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Phase 2Terminated 26 Aug 2022 KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Phase 2Unknown May 2024 Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Phase 1/2Unknown 11 May 2022 KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Phase 1/2Unknown Oct 2022 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Phase 1/2Terminated 27 Sep 2023 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Phase 1/2Unknown Nov 2024 Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Phase 1/2Unknown 31 Dec 2024 KRT-232 and TKI Study in Chronic Myeloid Leukemia
Phase 1/2Withdrawn Jun 2025 Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Navtemadlin

Following is part of Solo: you see every change to Navtemadlin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in